ChengweiPengMD

PubMed

• 11 citations
  KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
  Yuanwang Pan, Han Han, Hai Hu, Hua Wang, Yueqiang Song, Yuan Hao, Xinyuan Tong, Ayushi S Patel, Selim Misirlioglu, Sittinon Tang, Hsin-Yi Huang, Ke Geng, Ting Chen, An...> ;Cancer Cell. 2023 Jan 9
• 3 citations
  Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.
  Yuanwang Pan, Yuan Hao, Han Han, Ting Chen, Hailin Ding, Kristen E Labbe, Elaine Shum, Kayla Guidry, Hai Hu, Fiona Sherman, Ke Geng, Janaye Stephens, Alison Chafitz, S...> ;Journal for Immunotherapy of Cancer. 2022 Sep 1
• Phase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma.
  Lucas A Salas, Thomas G Stewart, Bret C Mobley, Chengwei Peng, Jing Liu, Sudan N Loganathan, Jialiang Wang, Yanjun Ma, Mitchell S Berger, Devin Absher, Yang Hu, Paul L...> ;Cancer Research Communications. 2022 Jan 1
• 23 citations
  Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
  , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Cancer Research. 2021 Oct 15
• 3 citations
  Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma
  Saad Saffo, Chengwei Peng, Ronald R. Salem, Tamar H. Taddei, Anil B. Nagar> ;Digestive Diseases and Sciences. 2021 Apr 3
• 11 citations
  Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma.
  Chengwei Peng, Deirdre Jill Cohen> ;Expert Opinion on Pharmacotherapy. 2021 Jan 2
• 1 citations
  Graft-Versus-Host Disease After Pancreatic Transplantation
  Saad Saffo, Chengwei Peng, Nour Kibbi, Natalie Patel, Marie E. Robert, Evelyn Adekolu, William S. Asch, Mayra Sanchez> ;ACG Case Reports Journal. 2019 Sep 12
• 32 citations
  Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.
  Keisha N. Hardeman, Chengwei Peng, B. Bishal Paudel, Christian T. Meyer, Thong Luong, Darren R. Tyson, Jamey D. Young, Joshua P. Fessel> ;Scientific Reports. 2017 Feb 16
• 16 citations
  Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab.
  Amanda Shreders, Richard W. Joseph, Chengwei Peng, Fei Ye, Shilin Zhao, Igor Puzanov, Jeffrey A. Sosman, Douglas B. Johnson> ;Cancer Immunology Research. 2016 Jul 1
• 12 citations
  Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience.
  Chengwei Peng, Jialing Wang, Jarred P. Tanksley, Bret C. Mobley, Gregory D. Ayers, Paul L. Moots, Stephen W. Clark> ;Molecular and Clinical Oncology. 2016 Feb 1
• 30 citations
  Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review
  Douglas B. Johnson, Chengwei Peng, Richard G. Abramson, Fei Ye, Shilin Zhao, Jeffrey A. Sosman, Richard D. Carvajal, Charlotte E. Ariyan> ;The Oncologist. 2015 Jun 1
• 100 citations
  Nivolumab in melanoma: latest evidence and clinical potential.
  Douglas B. Johnson, Chengwei Peng, Jeffrey A. Sosman> ;Therapeutic Advances in Medical Oncology. 2015 Feb 2
• Management of ‘pan-negative’ melanoma: current and emerging strategies
  Douglas B. Johnson, Chengwei Peng, Igor Puzanov> ;Melanoma Management. 2014 Dec 4
• Join now to see all